$1.44 +0.12 (9.09%) Arrowhead Pharmaceuticals Inc - NASDAQ

Dec. 2, 2016 | 04:00 PM

Quotes

  1. Quotes

  2. Charts

  3. Analysis

  4. Options

  5. Historical



Last Trade: 1.44
Trade Time: Dec 02 04:00 PM Eastern Daylight Time
Change: +0.12 (9.09%)
Prev Close: 1.32
Open: 1.40
Bid: 1.43
Ask: 1.44
  1. Mid-Day Market Update: Breitburn Energy Partners Drops Following News of Distribution Suspension; Mattress Firm Shares Surge

    Benzinga | Dec. 1, 2015 | 12:03PM EST
  2. Arrowhead Late-Breaking Clinical Data Shows that ARC-520 Can Produce Deep and Durable Reductions of Hepatitis B Viral Antigens and DNA

    Benzinga | Nov. 16, 2015 | 11:02AM EST
  3. US Stock Futures Edge Higher Ahead Of Empire State Manufacturing Index

    Benzinga | Nov. 16, 2015 | 07:07AM EST
  4. Arrowhead Presents Positive Data on ARC-520 in Hepatitis B Infected Chimpanzees at AASLD Liver Meeting 2015

    Benzinga | Nov. 15, 2015 | 18:43PM EST
  5. Benzinga's Top #PreMarket Gainers

    Benzinga | Oct. 13, 2015 | 07:17AM EST
  6. 10 Stocks Moving In Monday's After-Hours Session

    Benzinga | Sep. 28, 2015 | 15:47PM EST
  7. Arrowhead's good test result

    IBD | Sep. 24, 2015 | 17:35PM EST
  8. Arrowhead Hits Target In Hepatitis B Drug Trial

    IBD | Sep. 24, 2015 | 09:51AM EST
  9. Mid-Morning Market Update: Markets Tumble; Accenture Tops Q4 Estimates

    Benzinga | Sep. 24, 2015 | 09:33AM EST
  10. Morning Market Gainers

    Benzinga | Sep. 24, 2015 | 08:41AM EST
  11. Benzinga's Top #PreMarket Gainers

    Benzinga | Sep. 24, 2015 | 07:08AM EST
  12. Morning Market Gainers

    Benzinga | Sep. 11, 2015 | 08:48AM EST
  13. Arrowhead Initiates Dosing of ARC-AAT in Patients with Alpha-1 Antitrypsin Deficiency

    Benzinga | Jul. 2, 2015 | 06:33AM EST
  14. Can Hepatitis B Be A Blockbuster Bug?

    IBD | Jul. 1, 2015 | 07:02AM EST
  15. Arrowhead Receives Regulatory Clearance to Begin Additional Phase 2b Studies of Hepatitis B Candidate ARC-520

    Benzinga | Jun. 17, 2015 | 06:30AM EST
Trading Center